Webinar Summary
- T cell proliferative response is not altered by cryopreservation
- Cryopreservation does not change pro- or anti-inflammatory cytokines secretion profiles
- Cryopreservation does not alter the percentages of cell populations in PBMCs
- The data supports the more convenient use of cryopreserved PBMCs over freshly isolated cells
Human peripheral blood mononuclear cells (PBMCs) consisting of lymphocytes, dendritic cells and monocytes play an important role in both innate and adaptive immune systems. As such, PBMCs are increasingly being used in the drug development of biological therapeutics. Should you be concerned how cryopreservation will affect the various sub-populations of immune cells contained in your PBMC sample or performance parameters of those cells? Are you looking for more convenience in your immunology research workflows? Lonza scientists investigated what possible effects cryopreservation could have on the functionality of PBMC samples.
Presenters
Sarah Thacker
Sarah Thacker, PhD is a former Principle Scientist in the cell biology R&D group, at Lonza’s Center for Cell Excellence in Durham, NC, USA. While at Lonza Sarah lead R&D project initiatives to enable new product development as well as improvement upon existing products in the cell biology portfolio. Prior to working at Lonza, Sarah was a Biology Lead at Vitrisa Therapeutics, which involved developing biochemical and cell-based assays to screen and advance lead compounds targeted to treat ocular indications. Sarah holds a Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, and a Bachelor of Science in Chemistry from Washington College.
Aurita Menezes
Aurita Menezes, PhD is a Sr. market Development manager within the Marketing team at Lonza. In her role she is responsible for identifying products and product improvements that will serve the biologics and preclinical markets. Her portfolio focuses on hematopoietic immune and stem cells. She works closely with the Lonza R&D team to drive innovation with new primary cell products and assays. Aurita received her PhD in Microbiology and Immunology from University of Mississippi where she researched the major histocompatibility complex of Ictalurus punctatus. Previous to her role at Lonza she was a Sr. product manager at Integrated DNA technologies leading the development of qPCR gene expression and genotyping products.
Katherine Dunnick
Katherine (Katie) Dunnick, PhD is a Principal Process Engineer within the MSAT team at Lonza where she focuses on process improvement projects. Prior to her work in MSAT, she was a member of the Lonza R&D team working on the development of new primary cell products and assays. Katie received her PhD in Pharmaceutical and Pharmacological Sciences from West Virginia University where she researched the effects of nanoparticles on pulmonary systems, both in vitro and in vivo. After completing her PhD, she joined ScitoVation where she developed a novel assay to detect double strand DNA breaks via flow cytometry. She then joined MatTek as a Business Development/Marketing Manager prior to joining the Lonza MSAT team.
Sponsor
Lonza Group AG
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
